Dr. Subhdeep Virk, MD
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- Years since graduation
- 31
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 21
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
OH license 35.090284
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohio State University State Health System Columbus, OH
Medical groups
- Osu Psychiatry LLC (138 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 21
- Services billed
- 47
- Patients’ average age
- 62
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 30 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $322 in total to this clinician.
| Janssen Scientific Affairs, LLC | $200 |
|---|---|
| Lilly USA, LLC | $122 |
| Consulting Fee | $200 |
|---|---|
| Food and Beverage | $122 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Scientific Affairs, LLC Feb 14, 2025 | Consulting Fee SPRAVATO · Neuroscience | $200 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 4 companies. The companies reported $520,187 in research payments for these studies, mostly to the institutions running them.
- Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
AbbVie Inc. · Completed · NCT06605599 - A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD)…
Janssen Research & Development, LLC - A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorde…
Janssen Research & Development, LLC - A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)
Janssen Research & Development, LLC - A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disord…
Janssen Research & Development, LLC - Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderlin…
Boehringer Ingelheim International GmbH - Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
AbbVie Inc. · Recruiting · NCT06846320 - Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
AbbVie Inc. · Active, not recruiting · NCT07220460 - A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderl…
Janssen Research & Development, LLC - ITI-007-505
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.)
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.